Daniel Aaron Pollyea MD

PubMed

• Tamibarotene with venetoclax and azacitidine in RARAacute myeloid leukemia: results from the SY-1425-202 study.
  Thomas Cluzeau, Uma Borate, Christine McMahon, Pierre Fenaux, Mael Heiblig
  Blood Neoplasia. 2026-11-01
• Analysis of CD8 Cytotoxic T-Cells in Patients With Myelodysplastic Neoplasms and T-Cell Large Granulocyte Lymphocytic Leukemia.
  Makenna May, Nathaly Limon De la Rosa, Cassandra Duarte, Grace Boosma, Diana Abbott
  European Journal of Haematology. 2026-11-01
• 1 citations
  A phase 1/1b study of the all-oral regimen CC-486 and venetoclax in acute myeloid leukemia.
  Maria L Amaya, Diana Abbott, Christine McMahon, Marc Schwartz, Jonathan Gutman
  Blood Advances. 2026-10-13

Journal Articles

• Randomized Comparison of Low Dose Cytarabine with or Without Glasdegib in Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome  
  Daniel Pollyea, MD, Nature
• Venetoclax with Azacitidine Disrupts Energy Metabolism and Targets Leukemia Stem Cells in Patients with Acute Myeloid Leukemia  
  Daniel A Pollyea, Jonathan A Gutman, Enkhtsetseg Purev, Clayton Smith, Nature
• Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia  
  Brian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood

Abstracts/Posters

• A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantat...
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory ...
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based TherapiesClinically Relevant Abstract
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Data + Perspectives: Exploring the Role of Novel Agents and Emerging Strategies in the Management of Acute Myeloid Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Acute Myeloid Leukemia: Moving Beyond 7+3 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018